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When statins alone don’t work, 
think before writing a second prescription
When patients are unable to reach their lipid goal
on a single medication, they should first be 
evaluated for dietary noncompliance before adding
another medication that can be difficult to manage.
Unfortunately, the older bile acid sequestrants
have multiple drug interactions (ie, warfarin, 
digitalis, phenobarbital), and patients dislike them,
since they must remember to take other medica-
tions >1 hour before or >4 hours later (these 
problems are not seen with colesevelam, a newer
drug). Some physicians are reluctant to prescribe
statin/fibrate combinations due to the interaction of
gemfibrozil with statins; plus, patients must forego
grapefruit juice with fibrates to avoid toxicity.
Niacin has a low risk of toxicity, but fears of 
flushing may give patients pause (premedication
with aspirin can reduce flushing). Ezetimibe/statins
are effective, have relatively low toxicity and are
convenient due to availability of commercial 
combinations. When choosing medications, think
carefully about the patient before prescribing
another lipid-lowering medication.
Paul Crawford, MD
Eglin Air Force Base Family Medicine Residency, Eglin, Fla
Many combination drug therapies are effective in
treating dyslipidemia. Compared with statin
monotherapy, combinations that include ezetimibe
(Zetia), a bile acid sequestrant, or niacin further
lower low-density lipoprotein (LDL) cholesterol
(strength of recommendation [SOR]: A), and
increase the likelihood of attaining National
Cholesterol Education Program (NCEP) LDL 
cholesterol goals (SOR: B). Adding ezetimibe to a
bile acid sequestrant reduces LDL cholesterol
(SOR: B). Fibrate or niacin added to statin
monotherapy provide mixed lipid-modifying
effects for combined dyslipidemia (SOR: A). 
Most combination therapies increase the risk of
intolerance or side effects, including myopathy.
The statin/gemfibrozil combination has the 
highest risk of myopathy, whereas statin/
ezetimibe or statin/bile acid sequestrant have the
least increased risk (SOR: B). Studies evaluating
patient-oriented outcomes (morbidity, mortality)
with combination therapy vs monotherapy have
not yet been conducted; however, combination
therapies have demonstrated reduced athero-
sclerotic lesion progression. 
C L I N I C A L C O M M E N T A R Y
n Evidence summary
Hydroxymethyl glutaryl coenzyme A
(HMG CoA) reductase inhibitors, better
known as statins (atorvastatin, fluva-
statin, lovastatin, rosuvastatin, prava-
statin, simvastatin), have been shown to
lower LDL cholesterol in the primary
and secondary prevention of cardio-
vascular disease. Although often effective
as monotherapy, combination regimens
may be needed to reach LDL cholesterol
goals.1–4 Ezetimibe, niacin, and bile acid
sequestrants (cholestyramine [Questran],
colesevelam [WelChol], colestipol
[Colestid]) have complementary effects
that suggest they may be appropriate for
use in combination with a statin. 
Adding a bile acid sequestrant to
statin monotherapy does not appear 
to increase the risk of systemic toxicity.5
Joseph Saseen, PharmD, FCCP, Elizabeth Tweed, BSN, MLIS
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Ezetimibe, niacin,
and bile acid
sequestrants have
complementary
effects in 
combination 
with a statin
FAST TRACK
A systematic review found that adding
colestipol or cholestyramine to a statin
provides an additional 7% to 20%
absolute LDL cholesterol reduction.1 A
randomized placebo-controlled trial
demonstrated that combination therapy
with colesevelam has similar effects. The
absolute LDL cholesterol reduction of
with atorvastatin (Lipitor) alone (10 mg
daily) increased from 38% to 48% after
adding colesevelam 3.8 g daily (10%
absolute LDL cholesterol reduction).6
Statin/ezetimibe combination thera-
py is FDA-approved, and provides an
additional 12% to 21% absolute LDL
cholesterol reduction.2 Although consid-
ered safe, adding ezetimibe increases the
incidence of elevated hepatic transami-
nases from 0.4% to 1.3%.7 A double-
blind trial randomized 769 patients on
statin monotherapy who were above
their NCEP LDL goal to either placebo
or ezetimibe 10 mg daily.3 Absolute LDL
cholesterol reductions were 25.1% with
ezetimibe vs 3.7% with placebo, and
LDL goal attainment was 71.5% with
ezetimibe vs 18.9% with placebo (sec-
ondary endpoint). In one retrospective
analysis, ezetimibe provided a 19%
absolute LDL cholesterol reduction when
added to a bile acid sequestrant.8
Combinations of statins with fibrates
(fenofibrate [Tricor], gemfibrozil [Lopid])
can treat combined dyslipidemia by
decreasing LDL cholesterol more than
40%, decreasing triglycerides over 50%,
and raising high-density lipoprotein
(HDL) cholesterol more than 20%.9
Prospective controlled trials have shown
regression of atherosclerotic lesions with
this combination, but have also shown
increased risks of myopathy.6,10 In an
analysis of 36 controlled clinical trials
(1674 patients) that evaluated statin-
fibrate combinations, 0.12% of patients
developed myopathy, but none developed
rhabdomyolysis or kidney failure.10
Experts believe myopathy risk is greater
with gemfibrozil than fenofibrate, based
on gemfibrozil’s inhibition of statin glu-
curonidation, and case reports in the lit-
erature.5 Accordingly, the maximum
approved daily doses of lovastatin
(Mevacor), simvastatin (Zocor), and
rosuvastatin (Crestor) are lowered (20,
10, and 10 mg, respectively) when used
with gemfibrozil. 
Adding niacin to statin monotherapy
can modify combined dyslipidemia as
does a statin/fibrate combination, by low-
ering  LDL cholesterol and triglycerides,
and raising HDL cholesterol to an even
greater extent. Patients are more intoler-
ant to a statin/niacin combination (eg,
flushing) than to a statin/fibrate combina-
tion, but have a lower risk of myopathy
with the former.5 The combination of
statin/niacin may be more desirable than
statin/fibrate for patients with more
severe mixed dyslipidemia, especially
those with very low HDL cholesterol val-
ues, when monotherapy regimens are not
completely effective. A fixed combination
of lovastatin with extended-release niacin
(Advicor) is commercially available.4,11
Recommendations from others
The NCEP Adult Treatment Panel III rec-
ommends adding a bile acid sequestrant,
niacin, or ezetimibe to a statin when addi-
tional LDL cholesterol-lowering is needed
to reach NCEP-III goals, and adding
niacin or a fibrate to a statin to lower
non-HDL cholesterol for patients with
T A B L E
CHANGE CHANGE CHANGE 
COMBINATION IN LDL-C IN HDL-C IN TGD
Statin/bile acid sequestrant iii h i
Statin/ezetimibe iii h i
Statin/fibrate ii hh iii
Statin/niacin iii hhh iii
Ezetimibe/bile acid sequestrant ii h i
Key: One arrow, small change; 2 arrows, moderate change; 3 arrows, large
change. LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; TGD, triglycerides
Commonly used combination therapies 
with estimated changes in lipid values
Most combination
therapies 
increase risk 
of side effects,
including 
myopathy
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persistently high triglycerides or low
HDL cholesterol.12,13
The American Association of Clinical
Endocrinologists also recommends using
these combinations for the following 
circumstances: severe dyslipidemia, inad-
equate response to monotherapy, dose-
dependent adverse effects, and certain
mixed dyslipidemias.14 However, the clin-
ical advisory on statins by American
Heart Association/American College of
Cardiology/National Heart, Lung and
Blood Institute warns that statin/fibrate
combinations (especially with gemfi-
brozil) or statin/niacin (although rare)
are risk factors for statin-associated
myopathy.5
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